GLP-1 inhibitors are the class of molecules utilized for the treatment of T2DM. It works by activating GLP-1 receptor and is generally more potent in Hb1AC control, hypoglycemic variability and in patients with atherosclerotic cardiovascular disease as an added advantage.
This exclusive commentary briefs on the highlighting features of SGLP-1 inhibitors in the treatment of T2DM.
A Challenging Case of Pediatric Brain Abscess
Anatomy & Physiology
1m ago
8
China Reports First Commercial Brain-Computer Interface Implant for Spinal Cord Injury
Anatomy & Physiology
1m ago
0
Rare Triple Procedure Addresses Breast Cancer and Silent Cardiac Disease in One Operation
Cardiology
1m ago
0
Planning Complex Hernia Surgery: A Case-based Discussion
Surgery General
3h ago
3
India Adds Nearly 10,000 MBBS Seats for 2026 to 2027 Academic Session
Allergy & Immunology
4h ago
112
Which Therapy Directly Targets the Pituitary in Cushing Disease?
Endocrinology
5h ago
155